Rik Rademaker

Rik Rademaker is an accomplished director at Genmab since April 2011, with a robust background in molecular biology processes, antibody cloning, and bioinformatics. With a progression from Sr. Scientist to Director, Rik has developed expertise in high-throughput approaches, machine learning for antibody property prediction, and scientific data management. Prior experience includes a role as a scientist at Harbour Antibodies, focusing on biophysical characterization and custom bioinformatics tools, and a postdoctoral position at Erasmus MC in neuroscience research. Rik Rademaker holds a PhD in Gene Therapy from LUMC, where studies were conducted from 1998 to 2003.